MT 300: Phase III

Preliminary analysis of a double-blind U.S. Phase III trial in 619 acute migraine patients showed MT 300 met the primary endpoint

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE